Zobrazeno 1 - 10
of 221
pro vyhledávání: '"Miguel A. Villalona Calero"'
Autor:
Oliver H. Voss, Daniel Arango, Justin C. Tossey, Miguel A. Villalona Calero, Andrea I. Doseff
Publikováno v:
Cell Death and Disease, Vol 12, Iss 4, Pp 1-12 (2021)
Abstract Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selective killing of cancer cells underlines its anticancer potential. However, poor tolerability and resistance underscores the need to identify cancer-selective TRAIL-sensitiz
Externí odkaz:
https://doaj.org/article/f396aaa397634230b2ad7b3fbf1922c9
Autor:
Miguel A. Villalona-Calero, Jyoti Malhotra, Vincent Chung, Yan Xing, Stacy W. Gray, Heather Hampel, Stephen Gruber, Kevin McDonnell
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 12, p 4061 (2023)
Recent data suggest that patients with advanced cancer who participate in biomarker/genomically informed early-stage clinical trials experience clinical benefit. While most early-stage clinical trials are conducted in major academic centers, the majo
Externí odkaz:
https://doaj.org/article/451641aac1e74beca22c98414b6860f3
Autor:
Julian Ramelow, Christopher D. Brooks, Li Gao, Abeer A. Almiman, Terence M. Williams, Miguel A. Villalona-Calero, Wenrui Duan
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Lung cancer is the number one cancer killer worldwide. A major drawback in the lung cancer treatment field is the lack of realistic mouse models that replicate the complexity of human malignancy and immune contexture within the tu
Externí odkaz:
https://doaj.org/article/7d3855f9e97a42afa2bc6c08c7a8c23b
Autor:
Jennifer Novak, Ravi Salgia, Howard West, Miguel A Villalona-Calero, Sagus Sampath, Terence Williams, Victoria Villaflor, Erminia Massarelli, Ranjan Pathak, Marianna Koczywas, Brittney Chau, Arya Amini
Publikováno v:
Cancers, Vol 14, Iss 16, p 3983 (2022)
Tyrosine kinase inhibitor (TKI) therapy is the recommended first-line treatment for metastatic non-small-cell lung cancer (NSCLC) positive for epidermal growth factor receptor (EGFR) gene mutation. However, most individuals treated with TKI therapy f
Externí odkaz:
https://doaj.org/article/0f7bc28eceae4cc49ecbd0ae0d166bac
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Investigator-assessed best confirmed response to treatment with pazopanib and paclitaxel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9672b7ca2c278dae175f8f306ff555de
https://doi.org/10.1158/1535-7163.22502157.v1
https://doi.org/10.1158/1535-7163.22502157.v1
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Drug exposure for paclitaxel and pazopanib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0615d6fc6e040bc2461b00680e30c9f3
https://doi.org/10.1158/1535-7163.22502163
https://doi.org/10.1158/1535-7163.22502163
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Liver function tests for a cohort 1 patient with a hepatotoxicity dose-limiting toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c97eef3b4beb738ce9fbeba6e7dd48
https://doi.org/10.1158/1535-7163.22502169.v1
https://doi.org/10.1158/1535-7163.22502169.v1
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Pharmacokinetic data for a cohort 1 patient with hepatotoxicity dose-limiting toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a5cad2f0eaad56561c1dac53fb27a36
https://doi.org/10.1158/1535-7163.22502166
https://doi.org/10.1158/1535-7163.22502166
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Summary of paclitaxel pharmacokinetic parameters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bad83740a4222a581b1c5e31ac9d0f38
https://doi.org/10.1158/1535-7163.22502160
https://doi.org/10.1158/1535-7163.22502160
Autor:
James H. Doroshow, Richard M. Simon, Barbara A. Conley, Robert J. Kinders, P. Mickey Williams, Seth M. Steinberg, Paul M. McGregor, William D. Walsh, Michele G. Mehaffey, Chih-Jian Lih, Deborah E. Allen, Jiuping Ji, Alice P. Chen, Ahrim Youn, Peter M. Szabo, Robert J. Morgan, Miguel A. Villalona-Calero, Michael J. Naughton, David R. Gandara, Daniel M. Sullivan, Gini F. Fleming, Amit M. Oza, Shivaani Kummar
Supplemental Figure S1. Kaplan-Meier analysis of the progression free survival (PFS) of patients on each treatment arm stratified by BRCA status showed no significant differences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac78b660c4e98ad73ca9863a9f1c1ebb
https://doi.org/10.1158/1078-0432.22461263.v1
https://doi.org/10.1158/1078-0432.22461263.v1